Neil Versel

The company has committed at least $289 million to a partnership with Google Cloud to accelerate AI and other informatics.

The company, rebranded as Gedi Cube just two months ago, will become Renovaro.AI as it seeks to marry multiomics data and medical imaging in pursuit of faster cancer diagnoses and treatments.

A month into a collaboration with Nashville Biosciences, the Korean company is looking for additional partnerships with research institutions and Big Pharma to accelerate target discovery.

Bioinformaticians, researchers, and commercial software developers worldwide are trying to harness the power of generative AI for genomics without compromising scientific integrity.

The Swedish bioinformatics firm is targeting February 2025 for regulatory approval of its Qlucore Diagnostics software for transcriptomics-based ALL testing.

The specialty EHR vendor is building a two-way interface with Tempus as a model for incorporating genomic test ordering and results return into oncology workflows.

Initial results from a multinational rapid WGS newborn screening program are promising, though organizers hope to create a longitudinal study to support potential clinical uptake.

As Gero moves its operations from Russia and Singapore to the US, partner Foxo will provide longitudinal DNA methylation data to inform AI and validate recent research.

The Switzerland-based startup is also developing multiomics visualization and interpretation software to support drug discovery and biomarker ID.

Two separate papers from Korea and Qatar delved into using gene-specific machine-learning models versus disease-specific and genome-wide machine-learning methods for predicting pathogenicity.